INTEGRATED BIOPHARMA INC
For the period ended Mar 31, 2024. Filed May 10, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 10, 2024
INBPStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. EXHIBITS
(a) Exhibits
Exhibit
Number
| 10.1 | Fifth Amendment to Revolving Credit, Term Loan and Security Agreement dated as of May 16, 2024 by and among Integrated BioPharma, Inc., Manhattan Drug Company, Inc. (successor-by-merger to InB:Manhattan Drug Company, Inc.), Agrolabs, Inc., IHT Health Products, Inc. IHT Properties, Inc. and Vitamin Factory, Inc. and PNC Bank, National Association. | |
| 10.2 | Revolving Credit Note, dated as of May 9, 2024, by and among Integrated BioPharma, Inc., Manhattan Drug Company, Inc., Agrolabs, Inc., IHT Health Products, Inc., IHT Properties Corp. and Vitamin Factory, Inc. and PNC Bank, National Association, in the original principal amount of $5,000,000. | |
| 31.1 | Certification of pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by Chief Executive Officer. | |
| 31.2 | Certification of pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by Chief Financial Officer. | |
| 32.1 | Certification of periodic financial report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 by Chief Executive Officer. | |
| 32.2 | Certification of periodic financial report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 by Chief Financial Officer. | |
| 101.INS*** | Inline XBRL Instance | Furnished herewith |
| 101.SCH*** | Inline XBRL Taxonomy Extension Schema | Furnished herewith |
| 101.CAL*** | Inline XBRL Taxonomy Extension Calculation | Furnished herewith |
| 101.DEF*** | Inline XBRL Taxonomy Extension Definition | Furnished herewith |
| 101.LAB*** | Inline XBRL Taxonomy Extension Labels | Furnished herewith |
| 101.PRE*** | Inline XBRL Taxonomy Extension Presentation | Furnished herewith |
| 104 | Cover Page Interactive Date File (formatted as Inline XBRL and contained in Exhibit 101) |
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
INTEGRATED BIOPHARMA, INC.
| Date: May 10, 2024 | By: /s/ Christina Kay |
|---|---|
| Christina Kay, | |
| Co-Chief Executive Officer | |
| Date: May 10, 2024 | By: /s/ Riva Sheppard |
| Riva Sheppard, | |
| Co-Chief Executive Officer | |
| By: /s/ Dina L. Masi | |
| Date: May 10, 2024 | Dina L. Masi, |
| Chief Financial Officer & Senior Vice President |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.